生血宁片治疗围生期贫血的临床观察

Effect of Shengxuening Tablet on anemia in women during perinatal period

目的:观察生血宁片治疗围生期孕妇贫血疗效和不良反应发生情况。方法:采用前瞻性、随机、对照的临床研究,将已确诊为缺铁性贫血的围生期孕妇260例随机分为两组,每组各130例。治疗组口服生血宁片0.5g/bid(轻度)或0.5g/tid(中重度),对照组仅加强膳食营养指导,共观察8周。结果:治疗前生血宁片组与对照组在年龄、体重和血红蛋白(Hb)、红细胞(RBC)、血清铁蛋白(SF)和转铁蛋白饱和度等方面均无差异(P>0.05)。治疗后,治疗组Hb108.6±12.6g/L,RBC4.18±0.56×1012/L,SF12.26±4.38μmol/L,总铁结合力(TIBC)63.22±9.78μmol/L,显效率73.1%,有效率87.7%;而对照组显效率30.8%,有效率71.6%。结论:生血宁片治疗围生期贫血效果明显,无明显不良反应发生,是一种治疗围生期贫血的安全有效的药物。

Objective： To explore the effect of Shengxuening Tablet on anemia in women during perinatal period. Methods： A retrospective, randomised, controlled and clinical research was conducted. A total of 260 women with anemia during perinatal period were divided into two groups, and 130 women for each group. Women in the treatment group were given 0.5g of Shengxuening Tablet orally, twice a day for the mild anemia and three times each day for the moderate and severe anemia. Women in the control group were only guided for nutrition. Results ： Before the treatment, there were no significant differences in age, body weight, erythrocyte count, levels of hemoglobin, serum ferritin （SF） and transferrin saturation between the two groups. After the treatment, levels of hemoglobin, SF and total iron binding capacity in the treatment group were 108.6 ± 12. 6g/L, 12.26±4.38 mol/L and 63.22 ±9.78 mol/L, respectively, and the erythrocyte count was 4.18 ±0.56 ×10^12/L. The effective rates were 87.7% in the treatment group and 71.6% in the control group. Conclusion： Shengxuening Tablet is effective for the treatment of anemia in women during perinatal period.